life science - biopartner › documents › bes17.pdfthe uk life science directory is published by...

BIO-EUROPE SPRING 2017 UK Life Science 1

AT BIO-EUROPE SPRING 2017 M A R C H 2 0 - 2 2 B A R C E LO N A

Life ScienceUK DELEGATION PROFILES AND UK-BASED COMPANIES ATTENDING THE CONFERENCE

Internationalising UK Life Sciences

UK

BIO-EUROPE SPRING 2017 UK Life Science2

Translating UK scientific excellence into global therapeutic strategies

13 July 2017 Cambridge, UK

onhelix.com | join in the conversation #onhelix17

ON Helix is the established translational research conference brought to you by One Nucleus, which brings academia and industry together under one roof; bridging the gap between basic research and launching a product onto the market.

Our Keynote Addresses:

• Sharon Vosmek, CEO, Astia• David Tapolczay, CEO, MRC Technology• Sara-Jane Dunn, Microsoft

Wellcome Genome Campus Conference Centre, Cambridge

What to expect from the conference:

• ON Helix Welcome Reception and BioNewsRound Award | 12 July 2017• Interactive Panel Debates• 300 + Delegates• 30 Exhibitiors• 1-2-1 Partnering


Introduction

The UK Life Science Directory is published by Teamworks in partnership with BioPartner UK.

We are delighted to bring 45 UK companies to BIO-Europe Spring 2017, and to support an additional 170 who are independently registered*. Visit us at Booth 44 to find out more about UK expertise and make contact with companies attending from the UK. At BIO-Europe Spring 2017, we have around 220 companies from the UK at the event looking to forge profitable relationships. The UK is a natural trading partner for life sciences companies looking for innovative collaborations, access to academic excellence and entry to the European market.

The UK is one of the world’s strongest and most productive life sciences economies; it attracts almost 10% of the world’s pharmaceutical R&D funding and provides a uniquely fertile environment for the life sciences industry where businesses thrive. Innovation flourishes and is easy to commercialise; industry collaborates with academia and the health service; people are highly skilled and the Government is supportive.

The UK also continues to benefit from a globally admired regulatory regime, with two internationally recognised product approval agencies being based there. Small wonder, then, that the UK is a world-class trading partner in life sciences, as well as a leading investment location for life sciences businesses.

International representatives from BioPartner UK, the UK Bioindustry Association, Bionow, MediWales, One Nucleus and Scottish Development International will be present and available at BIO-Europe Spring 2017 and will be very happy to discuss how we can help maximise your business potential. *numbers correct at time of print

Translating UK scientific excellence into global therapeutic strategies

13 July 2017 Cambridge, UK

onhelix.com | join in the conversation #onhelix17

ON Helix is the established translational research conference brought to you by One Nucleus, which brings academia and industry together under one roof; bridging the gap between basic research and launching a product onto the market.

Our Keynote Addresses:

• Sharon Vosmek, CEO, Astia• David Tapolczay, CEO, MRC Technology• Sara-Jane Dunn, Microsoft

Wellcome Genome Campus Conference Centre, Cambridge

What to expect from the conference:

• ON Helix Welcome Reception and BioNewsRound Award | 12 July 2017• Interactive Panel Debates• 300 + Delegates• 30 Exhibitiors• 1-2-1 Partnering

www.teamworksdesign.com


Arcinova is focussed on providing a comprehensive

range of small molecule services from pre-clinical

through to market.

Your Trusted Partner...from Pre-clinical to Market

Strong expertise in APIroute selection, optimisation process development, and

scale up; including radiolabelled synthesis and impurity definition / control.

A comprehensive range of CMC services targeted,

principally, at piloting molecules through the

non-clinical and early clinical development phases.

Bioanalytical and metabolism services supporting

drug discovery and development needs from preclinical development

through to market.

Arcinova can provide advice and

support for preparation of

regulatory dossiers, particularly with

respect to the CMC content.

Formulation/process development studies are

conducted for non-clinical and clinical formulations based on

each molecule’s properties and the associated target

product profile

Drug development expertise and

support to assess the data from

your compound and provide

recommendations to achieve rapid drug

registration.

Tel: +44 (0) 1665 608300 Email: [email protected] Visit Us: www.arcinova.uk Taylor Drive, Alnwick, Northumberland, UK NE66 2DH


BioPartner UKBusiness sector: Network/Non-ProfitLin Bateson, Executive DirectorAlasdair Stamps, ChairmanBioPartner UK is your point of contact for the UK delegation to Barcelona. Visit us to find out more about doing business with UK companies, and to meet those in the UK delegation. BioPartner UK leads the UK Delegation to several partnering conferences each year. It is a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise. BioPartner has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.

www.biopartner.co.uk

Scottish Development InternationalBusiness sector: Network/Non-ProfitEmily Lekkas, International Senior Executive Katharina Kraehahn, International Senior Executive Scottish Development International offers free and confidential support to foreign companies who would like to identify commercial, clinical or academic partners in Scotland. SDI can also offer a wide range of investor support services for companies expanding in Europe.The Scottish Life Sciences sector consists of over 650 organisations employing over 32,500 people with particular strengths in cell and gene therapy, pharmaceutical services, digital health and clinical translational medicine.Scotland has a strong cluster of expert, innovative and ambitious companies delivering outsourcing solutions for biopharmaceutical companies globally. This includes both multi-national and niche CROs, innovative drug delivery and formulation specialists and manufacturing services that span drug development.Scotland is also in the top three centres for drug discovery and development in the UK and has a streamlined process for establishing clinical trials with fast approval times.

www.sdi.co.uk/invest/sectors/life-sciences

The UK Delegation


United Life SciencesBusiness sector: Network/Non-ProfitLin Bateson, BioPartner UKKaren Parr, UK BioIndustry AssociationLaura Collister, UK BioIndustry Association Amy Wright, BionowGwyn Tudor, MediWales Tony Jones, One NucleusUnited Life Sciences (ULS) is a strategic partnership representing over 1240 life science and healthcare organisations across the UK and internationally. The partnership was formed by four Founding Partners: the BioIndustry Association (BIA), Bionow, BioPartner UK and One Nucleus (ON) in 2014 and MediWales joined in 2015. The ULS collaboration has members and the wider UK life science sector at the heart of its purpose and is the basis for all joint activities. We strive to avoid duplication of effort and coordinate the founders’ activities whilst recognising each other’s areas of strength so that member companies can benefit from more effective and coherent sector support. Since 2012 ULS partners have worked together on a range of activities - including the creation and publication of a UK Life Science Manifesto 2015 - 2020, which is aimed at all political parties, and calls for the Biomedical Catalyst scheme to be continued in the interest of the nation’s health and wealth. ULS has also hosted a number of joint events both in the UK and overseas, and will be undertaking further joint initiatives plus providing cost effective attendance at each other’s events to maximise the international impact of the UK. Discounts are available to each other’s members for three of each of our major events so please check with your membership organisation for details.

www.unitedlifesciences.org

The one day event will be a valuable day of briefings and networking for those within the pharmaceutical and medtech communities. Over 300 delegates are expected to come together in an integrated congress to understand critical strategic trends that will impact on the life science industry. The event will offer both the latest insights from key opinion leaders and networking with regulatory authorities and executives from the world’s leading industry, clinical and research organisations.

4th December 2014, Cardiff, WalesLife Science Industry Conference

The UK HealthTech Conference 2014 is to be held at the St David’s Hotel, Cardiff.

Conference Rates:Delegate Rate £250 (£175 for MediWales Members)Exhibitor Packages £850 (£600 for MediWales Members)Sponsorship Packages from £2,000

* All prices exclude VAT

Dinner and Networking:Following this event there will be a drinks reception and dinner.

One Conference - Two Essential Streams • Pharmaceutical Development • Medical Technology

Partner Organisations


InvitationScottish Development International warmly invites you to join us at our

NETWORKING RECEPTION WITH SCOTCH WHISKY TASTING

Event: BIO-Europe SpringLocation: BioPartner UK at Booth #44

Date: Tuesday 21st MarchTime: 5.45pm

We look forward to seeing you there

www.sdi.co.uk @ScotDevInt


Imanova Advert

Imanova is a world-leading expert in imaging sciences and their application to the understanding of disease and translational drug development.

Our industry expertise and extensive links with clinicians and scientists in academia provide unrivalled capabilities to facilitate drug development.

Development of Novel Imaging BiomarkersWe have the capability and experience to help identify, evaluate, develop and implement biomarker candidates for use in both preclinical models and clinical (in human) studies.

Preclinical Imaging ServicesWe have extensive experience with supportive in vitro techniques, including autoradiography, radioligand binding and microscopy staining techniques, to correlate biological changes with quantitative imaging outcomes.

Clinical Imaging ServicesImanova provides state-of-the-art translational medicine capabilities by bringing together world class scanning know-how, radio-ligand development and imaging research methodology (PET and MRI).

Analysis and Consultancy ServicesOur scientists provide strategic input into drug discovery and development plans to optimise the use of imaging studies. This can contribute to a seamless transition from preclinical to clinical development and give answers to key early development questions.

+44 (0) 20 8008 6000 [email protected]


UK Delegation Member Companies

Almac DiscoveryBusiness sector: Biotherapeutics/DiagnosticsMartin Wiles, Vice President Business Development & LicensingAlmac Discovery: An oncology biotech with an extended reach.Cell cycle regulators, protein drug conjugates, ubiquitin specific proteases and effectors of the epithelial mesenchymal transition (EMT): All part of the oncology, discovery and early development pipeline of Almac Discovery.Our powerful competence in small molecule medicinal chemistry and protein and peptide engineering has enabled Almac Discovery to develop state-of- the-art platforms for both:- the discovery and validation of inhibitors of ubiquitin specific proteases, a large

untapped reservoir of potential therapeutic targets with biology important to a wide range of potential indications, and

- protein drug conjugates using shark derived binders to enhance tumour penetration.

We have partnering opportunities for cell cycle regulation with our Wee-1 inhibitor, a novel approach to tackling the cell cycle by driving division of damaged DNA, and also a Phase I EMT programme in development for ovarian cancer in the first instance.

www.almacgroup.com/discovery

Aptus ClinicalBusiness sector: R&D ServicesDr Steve McConchie, CEO Aptus Clinical is a specialist UK- based oncology clinical research organisation which helps life science companies to optimise their clinical development strategies and effectively transform promising molecules into valued medicines.What makes Aptus Clinical different is our flexibility – our clients benefit from our network of highly experienced and skilled experts from all technical disciplines, but only pay for what they need, when they need it. Our scientists have global expertise in all aspects of drug development so no challenge is too great, and being highly professional, they integrate seamlessly into a client organisation. This gives our clients all the benefits of an in-house clinical department, but at a significantly lower cost. In addition, our well-established relationships with some of the world’s leading experimental cancer centres, access to large patient populations and flexible arrangements to support optimal project delivery are just a few of the benefits to be gained from working with Aptus Clinical.Whether you need one-off consultancy support, clinical SOP implementation, expert medical or scientific input on a short or long term basis, or a full trial programme, we’d love to hear from you.

www. aptusclinical.com

Imanova is a world-leading expert in imaging sciences and their application to the understanding of disease and translational drug development.

Our industry expertise and extensive links with clinicians and scientists in academia provide unrivalled capabilities to facilitate drug development.

Development of Novel Imaging BiomarkersWe have the capability and experience to help identify, evaluate, develop and implement biomarker candidates for use in both preclinical models and clinical (in human) studies.

Preclinical Imaging ServicesWe have extensive experience with supportive in vitro techniques, including autoradiography, radioligand binding and microscopy staining techniques, to correlate biological changes with quantitative imaging outcomes.

Clinical Imaging ServicesImanova provides state-of-the-art translational medicine capabilities by bringing together world class scanning know-how, radio-ligand development and imaging research methodology (PET and MRI).

Analysis and Consultancy ServicesOur scientists provide strategic input into drug discovery and development plans to optimise the use of imaging studies. This can contribute to a seamless transition from preclinical to clinical development and give answers to key early development questions.

+44 (0) 20 8008 6000 [email protected]


Barrington JamesBusiness sector: Service/Consulting/MediaJames Lewis, Global Contracts DirectorSimon Allsop, DirectorMatthew Bulley, DirectorJonathan Jenkins, COOBarrington James are a global staffing and resourcing organisation who specialise in placing niche consultants of all levels in the Biotech and Pharmaceutical industry. We offer both short and long term solutions and can provide adhoc consultancy support as required. Our offices in Europe, USA and APAC means that we can provide a truly global solution and experience in a market you may not know.All of our team are dedicated market specialists with unrivaled candidate networks and will be on hand in Barcelona to discuss any assistance you may need to aid you getting your product to market. We have proven experience in knowing the difference between working for a big pharma and a new start-up biotech and will ensure that the people you hire truly understand your business and what you need to succeed.

www.barringtonjames.com

Cello HealthBusiness sector: Service/Consulting/MediaAdrian Watford, Vice President, Business DevelopmentJude Abernethy, Managing ConsultantCello Health is organised around three core capabilities - Insight, Consulting and Communications - which allows us to look at complex market challenges through ‘multiple lenses’. This enables us to help healthcare businesses unlock the potential of their assets, brands and organisations in a changing and challenging environment. The formation of Cello Health reflects industry pressure to optimise the potential of molecular assets and demonstrate value, recognises the loss of blockbusters, and the subsequent impact on available resources to bring brands to market. The Cello Health structure gives us a broader view of commercial and clinical success, and enables us to provide a greater depth and breadth of services to help support your critical decision making.

www.cellohealth.com


Clinical Network Services (UK) LtdBusiness sector: Service/Consulting/MediaPaul Cronin, DirectorClinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA. CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner. CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team. BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time. With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies. CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle.

www.clinical.net.au


Concept Life SciencesBusiness sector: Contract/R&D ServicesGordon Woodrow, Vice President – Business Development – Integrated Discovery ServicesConcept Life Sciences is a knowledge based, science led business focused on delivering the expertise and capabilities our clients demand. We are a European based contract research organisation of over 600 scientists providing drug discovery, development and analytical services to pharmaceutical and biotechnology clients globally. We can collaborate across all areas of your discovery and development programme as you progress from first concept to the launch of a finished product. Our highly trained scientists will provide support every step of the way from target to lead, lead to candidate and candidate to development.In discovery research, we provide expert services as individual elements or as a fully integrated discovery project delivering pre-clinical candidates. Our scientists are experienced in complex chemistry (synthesis), pharmacology and pathways analysis. By ensuring our medicinal chemists, our computational chemistry team, our synthetic chemistry and in vitro biology/ADMET departments are always working in step with each other we can accelerate the testing cycle.Moving through drug development and launch we have one of the widest ranges of analytical equipment available in Europe with specialist materials characterisation, chromatographic and spectroscopic services. Our pre-nomination support package covers comprehensive API characterisation, solubility/permeability/bioavailability determination and pre-formulation screening (excipient/salt/polymorph/crystallisation). We also have API processing capability including lyophilisation and micronisation services. We offer short and long term ICH stability studies, release testing and CMC support. Where required our services are cGMP certified. In addition, you can trust us to solve issues relating to the safety of compounds or selection of research candidates. We are experts in investigative and mechanistic toxicology, exploratory and discovery toxicology, PK and metabolism and dermal absorption.

www.conceptlifesciences.com


CTI Clinical Trial and ConsultingBusiness sector: Service/Consulting/MediaPatricia Havenga, International Senior Manager - Business DevelopmentCTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organisation (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialisation. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across six continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific.

www.ctifacts.com

DatatrialBusiness sector: Service/Consulting/MediaEmma Banks, CEODatatrial are a technology-focused business with a mature and elegant EDC system. We also offer a compliant document management solution and data storage. Our vision is to offer end-to-end documents to data and to include everything from discovery through to post marketing information in one easy to search environment. Key to this is making our platform accessible, both financially and from a user perspective, to small and mid-size businesses across a number of therapeutic areas or focuses (medical device, diagnostics and therapeutics). With headquarters in Newcastle upon Tyne, UK and offices in Boston MA and BioHub at Alderley Park, UK we are very able to support global clinical development programs. Since 1999, we have been serving the pharmaceutical community through our commitment to service and quality in every aspect of the work that we do. With involvement in over 300 clinical trials, across 25 therapeutic areas and with extensive oncology experience we will work with you to develop a software solution that best fits your needs.

www.datatrial.com


F-star Biotechnology LtdBusiness sector: Biotherapeutics/DiagnosticsF-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to create bispecific antibodies where the second binding site is in the constant Fc region of an antibody. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including AbbVie, Bristol-Myers Squibb, Merck Serono and Denali Therapeutics. F-star has currently one programme in the clinic with a second immuno-oncology programme heading towards IND. The company has built a comprehensive IP estate around its technology and product pipeline, with over 50 patent applications filed and over 25 granted patents.F-star’s management team has a well-established track record in building successful biotech companies, and developing biologics. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors. F-star has raised close to $100M in non-dilutive capital and revenues. The company currently employs over 80 people at its research site in Cambridge, UK.

www.f-star.com

Imanova LimitedBusiness sector: Contract/R&D ServicesDr Kevin Cox, CEOIan Hallett, Business Development ManagerImanova is a world-leading expert in imaging sciences and their application to the understanding of disease and translational drug development. Our industry expertise and extensive links with clinicians and scientists in academia provide unrivalled capabilities to facilitate drug development.Imanova has the state-of-the-art technology and skills to provide companies with quantitative data to accurately predict the effectiveness of a drug within human earlier within the drug development process, ensuring the resources are used efficiently and effectively.Our services include the development of novel Imaging Biomarkers, Clinical Imaging Services (PET and MRI), Preclinical Imaging Services, Analysis and Consultancy Services. We have the knowledge, experience and the expertise to provide end-to-end support to clients and collaborators.

www.imanova.co.uk


Karma Oncology LimitedBusiness sector: Contract/R&D ServicesDr Karen Williams, PresidentKarma Oncology is an oncology specialised contract clinical research company providing services to pharmaceutical and biotechnology companies. While specialised in oncology, we have expertise in many other therapeutic areas including cardiovascular, respiratory and female health amongst others. However, our service remains the same regardless of the therapeutic area – bespoke, flexible and innovative; where knowledge, commitment and communication are fundamental. Our services include clinical development planning, clinical trial protocol design & preparation, site selection, regulatory submissions, trial execution and reporting. Our team of experts is based across Western and Eastern Europe. All team members have a minimum of 10 years’ experience in their respective roles. We have been successfully partnering with companies with products in the late pre-clinical/early clinical phase of development since the company was established.

www.karmaoncology.com

Manchester Science PartnershipsBusiness sector: Service/Consulting/MediaDr Neil Jones, Science Service ManagerManchester Science Partnerships (MSP) is home to a unique community of scientists, innovators, investors and entrepreneurs and actively supports companies in the science, technology and innovation-driven sectors. Putting collaboration first and providing access to specialist finance, talent, markets, networks and investors enables MSP to support the acceleration of business growth through innovation. MSP’s unique partnerships across the science and technology sectors include The University of Manchester, Manchester Metropolitan University, Central Manchester University Hospitals NHS Foundation Trust (CMFT), Manchester City Council, Northern Health Science Alliance, Health Innovation Manchester, N8 and industry bodies such as BioNow and the BIA.As the UK’s leading science and technology park operator, with five campuses across North West England including Alderley Park in Cheshire, MSP is home to more than 300 high growth businesses and offers everything from specialist incubation centres to bespoke build laboratories and international centres of R&D excellence.It is our unique approach and unrivalled connections that enable companies in the MSP community to survive, grow, and thrive better than the local or national average – turning great ideas into commercial reality.www.alderleypark.co.uk

● 25 different Oncology indications….In both solid tumor and hematologic malignancies

● 10 different Therapeutic Approaches…..Including autologous cell therapy, selective internal radiation in addition to cytotoxics, targeted therapies and monoclonal antibodies

● 10 years ‘experience…..Every one of our Team Members has at least 10 years’ experience in their respective roles

www.karmaoncology.com [email protected]

A unique CRO, where experience makes the difference…..

KarmaOncology

KarmaOncology

Lowest turn-over rate in the Industry…. < 5% turn-over among CTAs, CRAs and Project Managers


MediWalesBusiness sector: Network/Non-ProfitGwyn Tudor, CEO MediWales is the life science network and representative body for Wales. An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales. MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally.

www.mediwales.com

MGB Biopharma LtdBusiness sector: R&D/BiotherapeuticsDr Miroslav Ravic, CEORaymond Spencer, CFOMGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise. Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens. Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing. MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections. MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

www.MGB-biopharma.com


Orla Protein Technologies LtdBusiness sector: Contract/R&D ServicesDr Dale Athey, CEOCornelia Wernhart, Business DevelopmentOrla Protein Technologies is a leader in recombinant protein design, engineering and manufacture, particularly for surface applications.We provide patented technology, products and bespoke contract services to companies and researchers for a wide range of Life Science applications such as bioanalytical devices, cell culture, bioseparations, and assay development. Our patented protein engineering platform, OrlaSURF, enables the creation of highly oriented and functional protein surfaces on a wide range of materials and formats such as plastic plates and microcarriers, glass slides, and gold biochips and nanoparticles. We offer bespoke contract protein design, expression and manufacture of proteins and protein surfaces.We welcome partners for access to our proprietary protein technology and expertise. We aim to help partners expand their product range, improve processes, accelerate product development and ultimately deliver added value. We are open to opportunities for out-licensing, collaboration, investment, acquisition and full-service customisation projects.

www.orlaproteins.com

Oxford GeneticsBusiness sector: Contract/R&D ServicesTom Speedy, Business Development ManagerOxford Genetics is a specialist synthetic biology company based in Oxford, United Kingdom, and our goal is to accelerate the discovery, development and production of proteins, antibodies, viruses and bio-therapeutics (biologics, gene/cell therapies) through the application of synthetic biology. We are focused on providing DNA, protein, virus and cell line solutions for mammalian expression and bio-production. From DNA design/synthesis, through antibody development, and using vectors to produce proteins/antibodies/viruses on the backend, Oxford Genetics delivers. Our team pride themselves on understanding the biological purpose of our customers’ projects, and work hand-in-hand to design, construct and validate the systems needed, providing a complete synthetic biology solution from design to delivery.

www.oxfordgenetics.com


SekisuiBusiness sector: R&D ServicesSekisui has been a leader in the manufacturing of high quality enzymes and specialist biochemicals to the global healthcare market for over 40 years. We have worked with many global partners to supply high quality materials for a variety of applications, including enzymes for bio-therapeutic manufacture, pharmaceutical production, clinical chemistry reagents, point-of-care / biosensor devices. We offer a process development, fermentation and purification competency.Sekisui is seeking to connect with Bio-Pharma Companies or Developers requiring contract manufacturing services, including process development or scale up where required. Our expertise resides in the manufacture of enzymes, proteins, or antibodies based on microbial fermentation.Further, we are seeking partners in contract manufacturing and with contract research organisations in the area of enzyme / protein development and manufacture for the Bio-Pharma sector.

www.sekisuienzymes.com

StratophaseBusiness sector: PharmaDermot Pearson, PhD Business Development Director - EuropeStratophase is a biotech services company that is revolutionising the timelines to clinic and commercialisation for biologics. We do this by rapidly optimising biomanufacturing processes using our Ranger technology to dynamically control the bioreactor environment in real time. Our Ranger® service and technology provide an innovative approach to bioreactor culture optimisation based on in-line, continuous assessment of the metabolic activity of the cell culture combined with a well established Probing Control Strategy. Ranger uses Adaptive Bioprocess Control to find and maintain optimal conditions that may vary over time during the manufacturing process. To do this we use our patented technology, combined with Stratophase’s extensive application expertise gained from over 300 customer processes and collaborations with industry-leading biopharma innovators, including GSK and Pfizer. Ranger’s adaptive and dynamic feed on demand capability, based on the metabolic demands of the bioreactor culture, is used to rapidly optimise the bioreactor process with either single or multi-component feed strategies, as demonstrated with our recently announced collaboration with Merck. The adaptive and scale-independent capability of Ranger delivers significant advantages to batch, fed batch and continuous manufacturing strategies, as well as autologous and allogeneic cell therapy processes.

www.stratophase.com


Virdis GroupBusiness sector: Service/Consulting/MediaNathalie Rowell, Head ConsultantGlobal Executive Search - Specialists in Lifesciences GROWTH - As your business develops you need other talented people to join your team and make their own contribution to deliver that new growth. Finding the right individuals is so much more than matching a set of skills and experience criteria.TRUST - At Virdis we are life-science specialists with years of international experience and a track record of finding exactly the people to help shape a company’s future. Our existing clients have trusted us with executive search assignments for years, and it is no surprise that our new clients come almost exclusively through personal recommendation.UNDERSTANDING - We are successful and we deliver; precisely because we take the trouble to understand your business and where you need to get to. You are the expert for your business; we are the experts in executive search. Together we establish what your business requires, and then we go to work for you, using our specialist Virdis network, extensive database and sheer determination to find them. OPPORTUNITY - Make the most of our experience and advice. At this International Partnering Conference take a few minutes for a conversation with Nathalie Rowell, our Senior Consultant.www.virdisgroup.com

XenoGesisRichard Weaver Managing DirectorXenoGesis Ltd. specialises in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. The core XenoGesis team has a proven track record of delivery in drug discovery. Through a consultative approach, the XenoGesis team helps to identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns, providing significant time and cost savings for R&D companies. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis. The organisation combines its state-of-the-art in vitro, in vivo and bioanalytical capabilities with its expert pharmacokinetic/pharmacodynamic (PK/PD) data interpretation services. Their laboratory tests demonstrate how the human body might affect the way a drug behaves, backed-up with advice on how to modify the chemical structure of a compound to make it more ‘drug-like’, this approach is what makes the XenoGesis service attractive to global drug companies.XenoGesis is a laboratory-based contract research organisation (CRO) based at BioCity Nottingham in the UK and works with clients across the globe.

www.xenogesis.co.uk


Biotherapeutics & Diagnostics

4D Pharma plcAbingdon HealthAlmac DiscoveryBenevolent AI LimitedC4X Discovery Holdings plcCaldan TherapeuticsCancer Research TechnologyCell & Gene Therapy CatapultCrescendo Biologics LtdDenceptor Therapeutics LtdDestiny Pharma LimitedF-star Biotechnology LtdGilead SciencesGlide TechnologiesGlythera LtdIontasKymabMGB Biopharma LtdMicroQuinMironidNeem Biotech LtdProAxsis LtdProximagenPsiOxus TherapeuticsReViralShield Therapeutics PlcSynpromicsSYNthesis ResearchTusk Therapeutics LtdValiSeek LimitedVernalis plc

Media

APM HealthBiopharm Insight (Mergermarket)Nature ResearchQuintilesIMS -

Global Market Insights R&D Solutions R&D Focus

Samedan LtdScrip & The Pink SheetSERMOSpringerNature

Pharma

3M United Kingdom PLCAccord HealthcareAlliance Pharmaceuticals LtdAspire PharmaEli Lilly and CompanyIpsenJohnson & Johnson InnovationMawdsleysMedPharm LtdMitsubishi Tanabe Pharma Europe LtdMSDNorgineRe-PharmStratophase LtdTeijin Pharma Ltd

Public / Non-Profit

BioPartner UKNewcastle UniversityNIHR Clinical Research NetworkOBNOne NucleusScottish Development InternationalUK BioIndustry Association (BIA)Ulster UniversityUlster University - Biomedical Science Research InstituteUnited Life SciencesUniversity of Leicester - Enterprise & Business DevelopmentUniversity of Southampton - Research & Innovation ServicesWellcome Trust

R&D Services

AbzenaAccelovance EuropeAdvanced Cell Diagnostics IncAlderley Park/Manchester Science PartnershipsApitope International N.V.AptusARCINOVABioAscent Discovery LtdChampions OncologyChiltern InternationalClinical AcceleratorCmedConcept Life SciencesCovance Inc.Critical Pharmaceuticals LtdCrystec LtdDatatrialDomainexEUSA PharmaEvotecFujifilm Diosynth BiotechnologiesFusion Antibodies LtdHORIZON DISCOVERYImanova LtdIsogenica LimitedKarma Oncology LimitedKWS BioTestKyowa Kirin International plcOrla Protein Technologies LtdOxford Genetics LtdPharmaterials LtdProimmune LtdQuay Pharmaceuticals LtdQuintiles LimitedRandox BiosciencesSekisuiSygnature DiscoverySyne qua nonTheradex EuropeVeristatXenoGesis Ltd

All attending UK companies


Services and Consulting

Aerotek Life SciencesAlacrita ConsultingApex Healthcare Consulting LimitedBarrington JamesBiotech and MoneyCello Health ConsultingCharles River AssociatesCIMYM BiosciencesClinical Network Services (UK) LtdColliers InternationalCoulter PartnersCTIDiamond BiopharmDRGEdisonERA Consulting UK LtdEuro Japan Marketing LimitedEvaluate Ltd

FormuliJ A KempLife Sciences Hub WalesMorgan Lewis & BockiusNovella ClinicalPatSnap ltdPhacilitatePharmalicensingPharmaVenturesProClinicalSixth Element Capital LLPSpencer StuartThe Fulford GroupThe Sage GroupTorreya PartnersTreehill PartnersVirdisGroupVolt Europe LtdWG Partners LLP

Investor

Boston University Radiology - Image Analysis GroupEpidarex CapitalERGOMED PLCMVM Life Science Partners LLPNorgine VenturesRothschild Medical Technology

Arrayjet LtdeLucid mHealth LtdGlycoMar LimitedHealthcare SourceKind Consumer

When identifying problems is not enoughSpecialists in preclinical drugmetabolism and pharmacokinetics(DMPK), quantitative bioanalysis and expert interpretation.

+44 (0) 115 837 0626 | [email protected] | www.xenogesis.comXenoGesis Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham, Nottinghamshire, NG1 1GF, UK

XG_QuaterPageAd_UK.qxp_Layout 1 07/03/2017 09:14 Page 1


BioPartner UK Delegations promote the UK presence at international conferences. We work with conference organisers, in-country agencies and overseas networks to provide the best discounts and business opportunities for UK companies travelling with the Delegation.

Representation on the UK exhibition standl Literature and business card display l Your company logo displayedl Optional pull-up display or full exhibit stand

Increased visibility as part of the groupl Profile in online and printed directoryl UK lapel pins for group members

Networking and referralsl Pre-event networking/briefing session

Organisational assistancel Conference booking, freight, itineraryl Pre-paid hotel close to the venue with discountsl Back-up: battery charging, disaster recovery

BioPartner UK DelegationsShowcasing UK Life Science

UK Delegation members gain significant extra promotion and networking opportunities at many of the biggest biopharma partnering events. BioPartner UK also provides access to government grants and enhanced entry fee discounts for UK-based SMEs.

“The work the BioPartner team do to provide hotel & logistic support makes the sole purpose for the vendor very easy to concentrate on conducting business. I cannot recommend their work enough.”Paul Kerr, Fusion Antibodies

“Being a member of BioPartner UK has enabled us to receive the best value, in terms of the unique discounts… being able to join the excellent UK Delegation, to receive representation on the UK stand, which is always a point of interest for attendees.”Adam Levy, ERA Consulting

Our Members Say:


BioPartner UK has negotiated exceptional discounts to some of the world’s highest quality biopharma partnering events. In partnership with United Life Sciences, we manage the UK presence at key overseas conferences.

The Future of Swedish & Danish Life Science30 March, LundUK Delegation + free to attend

BioTrinity8-10 May, London£300 discount

Anglonordic Life Science Conference 201731 May, London10% discount

Labiotech Refresh 20178 June, Berlin15% discount

53rd Annual DIA Meeting18-22 June, ChicagoUK Delegation + TAP grants

BIO Convention 201719-22 June, San DiegoUK Delegation + TAP grants + up to $600 discount

BioPharm America26-27 September, BostonDiscount $300

Bio-Europe 20176-8 November, BerlinUK Delegation + discount €350

Supported Events – Opportunities and Discounts

Opportunities - Partnering and Investment

Global Biopharma Boardroom Diversity28 March, London

DIA Bioventure Day28 Mar, Glasgow*

29th DIA Euromeeting29-31 March, Glasgow*

The Business of Precision Medicine5 April, Leeds

World Orphan Drug Congress USA19 Apr, Washington*

ChinaBio 201710-11 May, Shunde*

World Advanced Therapies & Regen Med Congress17-19 May, London*

Biodundee23 May, Dundee

MediWales Connects - NHS Collaboration Conference21 June, Cardiff*

MedFIT 201728-29 June, Grenoble*

BioFocus Conference 201729 June, Newcastle*

ON Helix Translational Research Conference13 Jul, Hixton*

BioPartner UK recommends a number of investor conferences and internationally focused events:

* BioPartner discounts apply. See our website for details of these and other opportunities. Join the BioPartnership Programme and be kept up to date!www.biopartner.co.uk/events.php



When your communicationsreally matter...

Crafting design & communications forscience, innovation and technology clients.

++

++

@teamworksdesign



When your communicationsreally matter...

Crafting design & communications forscience, innovation and technology clients.

++

++

@teamworksdesign www.karmaoncology.com [email protected]

Flexibility: Individual Services or Full Service Global CRO

Innovation: Novel approaches to save Sponsors time and money

Karma OncologyA unique CRO, where experience makes the difference…..and FITS

T

ITimeliness: Adherence to Sponsor timelines

SStability: Lowest turnover rate in the industry, <5% for CRAs, CTAs, and Project Managers

F

Your intellectual property assets are of great value to you. To help you to secure, protect and exploit them, you need technical experts who are also creative problem solvers. You need a team of specialists working together to pool their knowledge and resources in support of your business goals.

has one of the largest concentrations of biotech and pharmaceuticals patent expertise in Europe. No area of science or technology is outside our scope. So speak to us at BioEurope or contact us via our website at www.jakemp.com.

Representing J A Kemp at BioEurope 2017

“Commentators priase J A Kemp for their ‘intelligence, creativity and ingenuity’ and are delighted with the consistently high quality of their work.”

Chambers and Partners

“The services of J A Kemp have never let me down, thanks to their great in combination with different patent laws in all continents.”

Jos Seegers, former

CEO of Lactrys

Biopharmaceuticals and

Falco Biotherapeutics

Chris Milton Partner, Patent Attorney [email protected]

BIO-EUROPE SPRING 2017 UK Life Science26 creationvalue

Medicinal Chemistry

Bioscience

Computational Chemistry

DMPK

Sygnature Discovery is the UK’s

largest independent provider of

integrated drug discovery resource.

We add value to your research by

providing advanced scienti�c

knowledge and expertise to

accelerate your hit identi�cation,

hit to lead and lead optimisation

projects.

www.sygnaturediscovery.com

Sygnature Discovery LimitedBioCity, Pennyfoot StreetNottinghamNG1 1GFUnited KingdomT: +44 (0) 115 941 5401e: [email protected]

Half Page Ad 148x105:Layout 1 24/2/17 14:58 Page 1


London, May 31st, 2017Now entering its 14th year, AngloNordic continues to grow and gives you the opportunity to meet decision makers representing leading and upcoming R&D companies, international pharmaceuticals and investment firms.

Attend for close and focused interaction with R&D companies in the biotech and medical technology sectors. Investment pitches are interspersed with plenary sessions and panel discussions.

The conference starts the evening before (May 30th) with a drinks and canapes reception, and is free of charge to all delegates.

Sponsor or exhibitFor more information download the All You Need to Know brochure from the conference website, or to express an interest, email the conference team: [email protected]

PartnerMeeting MojoTM global partnering software enables participants to select the most suitable potential partners. The online booking system allows you to browse profiles, request meetings, set your own availability and promote your company to best advantage.

PitchApplications for investment pitches are open to medtech and biotech R&D companies. For information and to apply for a presentation please first apply for an invitation to attend at the website.

The conference has a“by-invitation-only” policy.

Service suppliers can attendas sponsors or exhibitors.

Investment companies attend free of charge.

R&D delegates can attend for a fee of £400+VAT per delegate.

www.anglonordiclifescience.com bit.ly/2lxBGo4@anglonordicN

S

To attend, partner, pitch, sponsor or exhibit visit


Champions Oncology is passionately dedicated to accelerating oncology drug development, improving patient outcomes, and extending lives. The Champions TumorGraft® platform of highly-characterized, clinically-relevant patient-derived xenograft (PDX) models is at the core of our advanced solutions that personalize the development and use of oncology drugs. Preclinical, translational and clinical investigators from biopharma companies utilizing the highly-predictive models can enhance the translatability of their research, advance emerging oncology therapies, study clinical patients, and derisk clinical trials. The technology also provides a diagnostic model that has been shown to be predictive of a patient’s individual clinical response to cancer treatment.

© 2017 Champions Oncology, Inc. All Rights Reserved. Champions TumorGraft is a trademark of Champions Oncology, Inc.

Predict Response. Predict Success. Creating Greater Certainty in the Fight Against Cancer

www.championsoncology.com

life science - biopartner › documents › bes17.pdfthe uk life science directory is published by...

Documents